Presentation to Highlight the Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Aug. 8, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced its President, Chief Executive Officer and Chief Financial Officer, Ryan Confer , will be providing an overview of the Company's gene therapies for cancer and diabetes at the upcoming Sidoti Microcap Conference.
Mr. Confer will deliver an overview of the Company's pioneering gene therapies for cancer and diabetes and will be available for virtual meetings with investors through the conference platform. An archive of Mr.
Confer's presentation will be available in the Investor Relations section of the Company's website. About Genprex, Inc. Genprex, Inc.
is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Genprex's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex works with world-class institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches.
Genprex's oncology program utilizes its systemic, non-viral Oncoprex® Delivery System which encapsulates the gene-.